To overcome therapy resistance in melanoma MEK inhibitors are tested in combination with a variety of drugs that use different approaches: inhibition of upstream Ras effectors, inhibition of PI3K-Akt-mTOR, inhibition of cell cycle regulators and activation of anti-tumor immunity but all seem to fail according to the existing cross-resistances [76]. The gene discussed is MTOR; the disease is melanoma.